(F22) From Clinic to Clicks: The Impact of Social Media on the Evolving Role of the DCES

Friday, August 7, 2026

3:50 PM - 4:35 PM ET

CE: .75 CE

People with diabetes increasingly turn to social media for answers, often before seeking care from a healthcare professional. While digital platforms offer connection and support, they also expose individuals to widespread misinformation that can delay treatment and cause harm. This session examines how social media is reshaping diabetes education and the evolving role of the DCES. Through expert perspectives and real-world examples, attendees will explore the benefits and risks of digital engagement and learn how the DCES can counter misinformation with evidence-based content. Participants will gain practical strategies and a proposed framework to responsibly integrate social media into DCES practice.

Learning Objectives:

At the completion of this activity, participants should be able to:

Describe the impact of social media on how people with or at risk for diabetes seek health related information.
Identify the risks and benefits of social media–based diabetes education, including strategies for addressing misinformation and preventing delays in care.
Outline best practices for ethical, evidence-based social media content and engagement, through real-world examples from effective digital creators.

Disclosure(s):

Rachael Sood, NP-C, CDCES: Dexcom: Speakers' Bureau (Ongoing); Eli Lilly: Consultant / Advisory Board (Ongoing); insulet: Consultant / Advisory Board (Ongoing); Medtronic Diabetes: Consultant / Advisory Board (Ongoing); Mounjaro Metabolic Faculty: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing); Sequel med tech: Consultant / Advisory Board (Ongoing)

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP: Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Dexcom: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Mannkind: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Tandem: Consultant / Advisory Board (Ongoing)

Primary Presenter(s)

Rachael Sood, NP-C, CDCES

CEO
The Diabetes Collective

Disclosure(s): Dexcom: Speakers' Bureau (Ongoing); Eli Lilly: Consultant / Advisory Board (Ongoing); insulet: Consultant / Advisory Board (Ongoing); Medtronic Diabetes: Consultant / Advisory Board (Ongoing); Mounjaro Metabolic Faculty: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing); Sequel med tech: Consultant / Advisory Board (Ongoing)

Co-Presenter(s)

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP (she/her/hers)

Endocrine Clinical Pharmacy Specialist
Cleveland Clinic Endocrinology & Metabolism Institute

Disclosure(s): Abbott: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Dexcom: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Insulet: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Lilly: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Mannkind: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Tandem: Consultant / Advisory Board (Ongoing)